- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Drug discovery
Lilly hopes Elanco unit becomes a cash cow
May 8, 2010
J.K. WallElanco Animal Health chief Jeff Simmons predicts that consumers will opt for food made cheaper by using
Elanco's productivity-enhancing drugs over pricier organic and locally grown products. But, as a hedge,
he has Elanco developing products to help organic farmers, too.
MoreChao exit hurts drug development industry
April 28, 2010
J.K. WallPurdue University’s decision to close the Chao Center in West Lafayette is a setback for Indiana’s effort to grow
a vibrant contract drug manufacturing sector. But it’s just the latest in a series of unexpected changes—not all
for
the worse—since Indianapolis-based BioCrossroads launched a contract drug manufacturing initiative in late 2007.
MoreHarlan Labs names new CEO
April 23, 2010
IBJ StaffThe Indianapolis-based provider of clinical research animals has promoted senior manager Hans Thunem to its top spot.
MoreAriad loses $65M patent appeal against Eli Lilly
March 22, 2010
Bloomberg NewsMonday's decision throws out a $65.2 million patent-infringement verdict won by Ariad for royalties on Lilly's osteoporosis
drug Evista and sepsis medicine Xigris.
MoreLilly sues to block generic of Adcirca lung treatment
March 17, 2010
Bloomberg NewsNetherlands-based Synthon Pharmaceuticals is seeking U.S. Food and Drug Administration approval to sell a copy of the medicine.
MoreLilly pays $50M-plus for rights to testosterone lotion
March 16, 2010
Bloomberg NewsIndianapolis-based Lilly will pay Acrux of West Melbourne, Australia, a $50 million license fee, plus $3 million when manufacturing
assets are transferred, but the deal could be worth millions more.
MoreTo attack costs, Lilly accelerates R&D
March 3, 2010
J.K. WallWith President Barack Obama looking to squeeze a bit more revenue out of the pharmaceutical industry, the stakes just keep
getting higher for Eli Lilly and Co.'s efforts to develop drugs faster and cheaper.
MoreTeva gets European OK to sell generic of Lilly's Evista
February 19, 2010
Bloomberg NewsEvista generated $1.03 billion in sales last year, of which $348.1 million came outside the United States.
MoreLilly looks to autoimmune drugs
January 27, 2010
J.K. WallTwo local researchers show why Eli Lilly and Co. and its peers are interested in developing medicines to treat automimmune
diseases: The costs of treating them are growing twice as fast as the prescription drug market.
MoreLilly shares get boost from OK of rival's drug
January 26, 2010
IBJ Staff and Bloomberg NewsShares of Lilly and partner Amylin rose on hopes that their new version of Byetta will be approved following U.S. regulators'
clearance of a similar drug.
MoreEli Lilly's shares slip after it forecasts mixed profits in coming years
December 10, 2009
IBJ Staff and Associated PressThe Indianapolis-based drugmaker predicts strong profits through 2011, but its forecast for 2012 suggests bottom-line results
could fall precipitously.
MoreLilly launching new venture capital fund
December 10, 2009
J.K. WallThe fund would acquire experimental drugs and use Lilly R&D staff to try to prove their effectiveness, perhaps boosting Lilly's
drug pipeline.
MoreLilly extends research pact with India firm
December 1, 2009
IBJ StaffJubilant Organosys Ltd. and Indianapolis-based Eli Lilly and Co. extended their collaboration, which began in 2005, by five
years.
MoreLilly stock droops after rival claims faster-acting impotence pill
November 18, 2009
IBJ StaffCalifornia-based Vivus claims its drug acts in 30 minutes, compared with about 2 hours for Lilly's Cialis.
MoreAarden Pharmaceuticals chose Indianapolis over San Diego for headquarters
November 14, 2009
IBJ StaffThanks partly to a state grant and support from Indiana’s BioCrossroads life sciences initiative, principals “decided
locating here would give Aarden a better chance of success.
MoreEli Lilly CEO banking on new drug pipeline
October 22, 2009
Associated PressCEO John Lechleiter says Lilly's pipeline has helped it rebound from significant patent losses three times during his 30-year
career at the company. He's betting there will be a fourth.
MoreLilly, GE announce cancer diagnostic breakthrough
October 21, 2009
J.K. WallEli Lilly and Co. and General Electric Co. say they've made a breakthrough in cancer research that could help Lilly cut the
size and cost of its clinical trials.
MoreEndocyte receives $26M infusion from investors
October 16, 2009
West Lafayette-based Endocyte Inc. announced Friday that it has closed on $26 million in equity financing to help the company
continue developing cancer-fighting drugs.
MoreLilly's win in Evista patent case crucial, analyst says
September 24, 2009
Scott OlsonA decision by a federal judge in Indianapolis to turn back a patent challenge to Eli Lilly and Co.'s Evista marks a major
victory for the company, says an analyst who closely follows the pharmaceutical industry.
MoreUPDATE: Pipeline challenges force Lilly restructuring moves
September 14, 2009
J.K. WallSince John Lechleiter was named CEO 18 months ago, he's bet that Eli Lilly and Co. could face down its looming patent challenges
by launching innovative new medicines. Today's announcement of 5,500 job cuts by the end of 2011 and a restructuring of the
company's business units ups the ante on that bet, while indicating that it isn't working yet.
MoreLilly reorganization to cut 5,500 positions over 2 years
September 14, 2009
J.K. WallEli Lilly and Co. will cut 5,500 jobs by the end of 2011 as it tries to cut $1 billion in expenses before it loses revenue
from its bestselling drug, Zyprexa. Lilly CEO John Lechleiter said he did not know how many of those cuts would occur in central
Indiana. But with
13,600 employees working in the Indianapolis area, he acknowledged the largest chunk of reductions likely would come here.
MoreLilly drops osteoporosis pipeline drug
August 18, 2009
J.K. WallEli Lilly and Co. pulled the plug on yet another drug in its pipeline that was in the late stages of testing, further complicating
the company’s attempts to find revenue before losing patent protection on its bestseller.
MoreLilly's Effient launch just one of its many challenges
August 3, 2009
Greg AndrewsEli Lilly and Co. has blasted past analysts’ earnings projections for two straight quarters. But if Lilly officials
take that as a sign they can breathe easier, they need only flip through a stack of Wall Street research reports on the company.
MoreLilly cancels trials for experimental MS drug
July 28, 2009
J.K. WallEli Lilly and Co. and a development partner has canceled clinical trials on an experimental drug to treat multiple sclerosis
after the drug failed to delay progression of the disease in trial patients.
MoreProfessors go online to revolutionize drug discovery
July 20, 2009
IBJ StaffTwo chemistry professors at IUPUI are laboring to create the McDonald’s of research laboratories—low-cost and
all over the world.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
Ameriana Bank took over Westfield Farmers Market for 2013 and it is held in their parking lot, corner of 32 and Carey road, 5 to 8. I am selling soap and candles there. great market!
B&T certainly has enough of our taxpayer dollars to do this thanks to Mayor Ballard. Given the firm's exceedingly poor reputation in the legal community, the basement would seem a better option.
Should read MAY hire 20 people.
Not a good location for a 300,000 home. 10th Street fumes, buses, noise. Max for this location 150,000.
The state constitution also does not say that the majority has a right to quorum, nor that the minority is required to allow them quorum. In fact, denial of quorum has been a parliamentary maneuver since the establishment of the first parliaments in the early 1600s. The right to deny quorum (and the requirement fore quorum) are to prevent exactly what happened in Indiana: A tyrannical majority pushing through odious, objectionable legislation. Denial of quorum is totally legitimate, and lest we forget, a tactic the GOP has employed many, many times to ensure their issues weren't given short shrift. By allowing the majority to impose "fines" on the minority for exercising the authority the constitution grants them (to deny quorum,) they are violating the constitution.